Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ProMIS Neurosciences Inc. - Common Shares
(NQ:
PMN
)
7.625
+0.265 (+3.60%)
Streaming Delayed Price
Updated: 10:35 AM EST, Dec 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ProMIS Neurosciences Inc. - Common Shares
< Previous
1
2
3
Next >
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
December 01, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
December 01, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
November 12, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 03, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
October 22, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
September 03, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
August 13, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
July 29, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Private Placement Financing
July 28, 2025
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Private Placement Financing
July 22, 2025
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
July 21, 2025
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends “FOCUSfactor” Exploding Across North America – More Stocks Inside
July 14, 2025
Via
AB Newswire
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 17, 2025
Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ET
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
May 12, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
March 31, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
March 24, 2025
Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
March 13, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
March 11, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
February 25, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
January 13, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
January 10, 2025
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
November 26, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
November 14, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 12, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
October 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 12, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
